Chabiotech Co.,Ltd. (KOSDAQ:085660)
11,300
-310 (-2.67%)
Jun 10, 2026, 3:30 PM KST
Chabiotech Revenue
Chabiotech had revenue of 329.71B KRW in the quarter ending March 31, 2026, with 8.41% growth. This brings the company's revenue in the last twelve months to 1.29T, up 15.85% year-over-year. In the year 2025, Chabiotech had annual revenue of 1.27T with 21.36% growth.
Revenue (ttm)
1.29T
Revenue Growth
+15.85%
P/S Ratio
0.83
Revenue / Employee
4.65B
Employees
278
Market Cap
1.07T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27T | 223.20B | 21.36% |
| Dec 31, 2024 | 1.05T | 91.10B | 9.55% |
| Dec 31, 2023 | 953.95B | 109.37B | 12.95% |
| Dec 31, 2022 | 844.58B | 117.11B | 16.10% |
| Dec 31, 2021 | 727.48B | 62.76B | 9.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| SK bioscience | 665.42B |
| PharmaResearch | 565.48B |
| Hugel | 451.93B |
| Medy-Tox | 244.02B |
| MEDIPOST | 73.90B |
| Onconic Therapeutics | 67.20B |
| Pharmicell | 23.94B |